WithdrawnNot Applicable

Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction

Stopped: Administrative-not IRB approved

0Started 2022-07

Plain-language summary

The aim of this project is to identify if EndoFLIP can categorize and change the diagnosis in patients with EGJOO and if categorization with EndoFLIP can predict the response to treatment with botulinum toxin at 12 weeks post procedure. Our hypothesis is that there will be greater symptom resolution in the treatment versus control in the abnormal DI category. In addition, we hypothesize there will be less symptom resolution in the control group with an abnormal DI as compared to those with a normal DI who also receive no treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * diagnosed with esophagogastric junction outflow obstruction by high resolution manometry Exclusion Criteria: * previous upper gastrointestinal surgery * significant medical co-morbidities * eosinophilic esophagitis * severe reflux esophagitis (LA-classification C or D) * large hiatal hernia * patients experiencing significant weight loss suspicious for malignancy * Vulnerable populations such as cognitively or decisionally impaired individuals, children, pregnant women, prisoners, and students or employees of the University of Kansas Health System or Medical Center

What they're measuring

Symptom Resolution

Timeframe: 12 weeks.

Trial details

NCT IDNCT04938102

SponsorUniversity of Kansas Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07

View on ClinicalTrials.gov More Esophagogastric Junction Disorder trials